Exelixis
EXEL
#1725
Rank
NZ$16.81 B
Marketcap
$58.86
Share price
-1.16%
Change (1 day)
57.81%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) Fails to deliver data

Key failure to deliver metrics for Exelixis:

A Failure to deliver also known as fails-to-deliver or FTD occurs when a buyer or seller is unable to meet his trading obligations. FTDs for US listed companies are reported to the SEC and published twice a month. Therefore there is a certain delay between the reporting and the publishing of the data.

Failures to deliver for Exelixis (EXEL) - 3 months history

Number of shares, 3 months chart

Biweekly Failures to deliver volume for Exelixis (EXEL) - since 2013

Volume in USD (price x number of shares), data since 2013

Exelixis (EXEL) Failure to deliver volume, Year over Year

Year Volume (Price x Shares) Change
2024NZ$9.86 M52.17%
2023NZ$6.48 M-41.81%
2022NZ$11.14 M-31.9%
2021NZ$16.36 M-20.71%
2020NZ$20.64 M303.63%
2019NZ$5.11 M-70.5%
2018NZ$17.33 M8.82%
2017NZ$15.92 M-17.35%
2016NZ$19.27 M-75.68%
2015NZ$79.23 M19.37%
2014NZ$66.37 M258.49%
2013NZ$18.51 M

FTD volume in the last 3 months for similar companies or competitors

Company FTD volume (3 months) FTD volume (1 year) Country
NZ$57.35 MNZ$99.79 M๐Ÿ‡ฌ๐Ÿ‡ง UK
NZ$11.17 MNZ$72.51 M๐Ÿ‡ซ๐Ÿ‡ท France
NZ$24.78 MNZ$98.35 M๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$43.55 MNZ$0.32 B๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$62.92 MNZ$0.25 B๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$81.31 MNZ$0.33 B๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$48.65 MNZ$0.35 B๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$0.26 MNZ$1.26 M๐Ÿ‡บ๐Ÿ‡ธ USA
N/ANZ$0.04 M๐Ÿ‡บ๐Ÿ‡ธ USA